Material Information- Announcement on behalf of the subsidiary, Handa Pharma, Inc, regarding the change in over one-third of directors
1.Date of occurrence of the change:2026/11/05
2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): Institutional director
3.Title and name of the previous position holder: George Kraft
4.Resume of the previous position holder: Vice President of Corporate Development Department of Handa Pharma, Inc
5.Title and name of the new position holder: Qiao Li
6.Resume of the new position holder: Chief Operation Officer of Handa Pharma, Inc
7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”): Appointment of a representative by the institutional director
8.Reason for the change: Appointment of a representative by the institutional director
9.Number of shares held by the new position holder when elected: NA
10.Original term (from __________ to __________):NA
11.Effective date of the new appointment:2026/11/05
12.Turnover rate of directors of the same term:1/3
13.Turnover rate of independent directors of the same term: NA
14.Turnover rate of supervisors of the same term: NA
15.Change in one-third or more of directors (Please enter “Yes” or “No”): Yes
16.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): None